Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LonGEVity: Venetoclax + Obinutuzumab Followed by Epcoritamab in Untreated CLL/SLL
NCT07218510Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jan 2026
- Primary completion
- Jun 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by City of Hope. Started Jan 2026; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07218510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218510.